Neda Cramer

Dr. Neda Cramer

Auto-generated profile, based on publicly available information

Dr. Neda Cramer


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
NCNeda Cramer
Neda Cramer
PWPhoebe Wellmann
Phoebe Wellmann
MSMichael Schoen
Michael Schoen
RMRotraut Mössner
Rotraut Mössner

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
NCNeda Cramer
Neda Cramer
DKDaniel Kromer
Daniel Kromer
JBJulia M. Bootsveld
Julia M. Bootsveld
SGSascha Gerdes
Sascha Gerdes
PSPetra Staubach-Renz
Petra Staubach-Renz
RMRotraut Mössner
Rotraut Mössner
Background and Objectives: Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real‐world conditions. Patients and Methods: Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression. Results: Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, p = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF‐α blockers and IL‐17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one‐third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; P = 0.013, χ 2 ‐test). Conclusions: In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.

27 September 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
NCNeda Cramer
Neda Cramer
JMJohannes Mohr
Johannes Mohr
MSMichael Schoen
Michael Schoen
RMRotraut Mössner
Rotraut Mössner

16 February 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
NCNeda Cramer
Neda Cramer
DKDaniel Kromer
Daniel Kromer
JBJulia M. Bootsveld
Julia M. Bootsveld
SSSabine Sennhenn‐Kirchner
Sabine Sennhenn‐Kirchner
SGSascha Gerdes
Sascha Gerdes
RMRotraut Mössner
Rotraut Mössner
Summary: Background and Objectives: Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging. Patients and Methods: In this cross‐sectional study, a wide range of characteristics of the patient's journey were assessed and evaluated from a total of 72 patients with mucosal LP who were treated in the dermatology departments of six German university medical centers between 02/2022 and 07/2023. Results: On average, 18.1 months elapsed between the onset of symptoms and diagnosis. Until the correct diagnosis was made, an average of 3.1 different physicians of the same or different specialties were consulted. 28.1% of patients also had cutaneous involvement. Therapeutically, 68% of patients received at least one systemic drug. Both topical (90%, 65/72) and systemic (oral, 50% of patients, 36/72; intravenous, 33%, 24/72) glucocorticoids were most frequently used. Systemic agents were most often discontinued due to ineffectiveness (46%, 50/110). Satisfaction with treatment was highest for intravenous and topical glucocorticoids (moderate to high satisfaction: 59% and 36%, respectively), and lowest for retinoids with 8%. Conclusions: This study indicates that there might be a lack of diagnostic awareness among physicians and the unmet need for effective systemic treatment options.

20 December 2023 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
NCNeda Cramer
Neda Cramer
SISara Isik
Sara Isik
SFSusann Forkel
Susann Forkel
MSMichael Schoen
Michael Schoen
TBTimo Buhl
Timo Buhl

8 April 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
NCNeda Cramer
Neda Cramer
DKDaniel Kromer
Daniel Kromer
JBJulia M. Bootsveld
Julia M. Bootsveld
SSSabine Sennhenn‐Kirchner
Sabine Sennhenn‐Kirchner
SGSascha Gerdes
Sascha Gerdes
RMRotraut Mössner
Rotraut Mössner
Zusammenfassung: Hintergrund: Der Lichen ruber mucosae (LRM) ist eine chronische entzündliche Erkrankung. Der Weg des Patienten mit der Krankheit kann schwierig sein, da die Diagnosestellung und Therapie eine Herausforderung darstellen. Patienten und Methodik: In dieser Querschnittsstudie wurden bei insgesamt 72 Patienten mit LRM, die zwischen 02/2022 und 07/2023 in den dermatologischen Abteilungen von sechs deutschen Universitätskliniken behandelt wurden, eine Vielzahl von Charakteristika zum Krankheitsverlauf erfasst und ausgewertet. Ergebnisse: Zwischen dem Auftreten der Symptome und der Diagnosestellung lagen im Durchschnitt 18,1 Monate. Bis zur korrekten Diagnosestellung wurden durchschnittlich 3,1 verschiedene Ärzte der gleichen oder anderer Fachrichtungen konsultiert. 28,1% der Patienten hatten auch eine Hautbeteiligung. Therapeutisch erhielten 68% der Patienten mindestens ein systemisches Medikament. Sowohl topische (90%, 65/72) als auch systemische (oral, 50%, 36/72; intravenös, 33%, 24/72) Glukokortikoide wurden am häufigsten eingesetzt. Systemische Medikamente wurden am häufigsten wegen Unwirksamkeit abgesetzt (46%, 50/110). Die Zufriedenheit mit der Behandlung war bei intravenösen und topischen Glukokortikoiden am höchsten (mittlere bis hohe Zufriedenheit: 59% bzw. 36%) und bei Retinoiden mit 8% am niedrigsten. Schlussfolgerungen: Die Ergebnisse dieser Studie deuten darauf hin, dass das diagnostische Bewusstsein der Ärzte möglicherweise unzureichend ist und dass ein Bedarf an wirksamen systemischen Therapien besteht.